Plasma microRNA biomarkers for detection of mild cognitive impairment: Biomarker validation study

Aging

Volumn 5, Issue 12, 2013, Pages 925-938

  Sheinerman, Kira S ^a   Tsivinsky, Vladimir G ^a   Abdullah, Laila ^b   Crawford, Fiona ^b   Umansky, Samuil R ^a  

^a DiamiR LLC   (United States)

^b ROSKAMP INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Brain; Circulating; MicroRNA; Mild cognitive impairment (MCI); Neurodegeneration; Plasma; Synapse

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

AGED; AGING; ARTICLE; BLOOD; CASE CONTROL STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; REPRODUCIBILITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; REPRODUCIBILITY OF RESULTS;

EID: 84891525727     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100624     Document Type: Article

References (36)

1. Gerald Z, Ockert W. Alzheimer's disease market: hope deferred. Nat Rev Drug Discov. 2013; 12:19-20.
2. Dorsey ER, George BP, LeffB, Willis AW. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology. 2013; 80:1989-1996.
3. Snyder EM, Olin J, David FS. Maximizing the value of diagnostics in Alzheimer's disease drug development. Nat Rev Drug Discov. 2012; 11:183-184.
4. Karakaya T, Fußer F, Schröder J, Pantel J. Pharmacological Treatment of Mild Cognitive Impairment as a Prodromal Syndrome of Alzheimeŕs Disease. Curr Neuropharmacol. 2013; 11:102-108.
5. Henriksen K, O'Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, Blennow K, Lönneborg A, Wyss-Coray T, Soares H, Bazenet C, Sjögren M, Hu W, Lovestone S, Karsdal MA, Weiner MW; Blood-Based Biomarker Interest Group. The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement. 2013 Jul 11 [Epub ahead of print].
6. Cunningham EL, Passmore AP. Drug development in dementia. Maturitas. 2013 May 23. [Epub ahead of print].
7. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement. 2013 Aug 6 [Epub ahead of print].
8. Pillai JA, Cummings JL. Clinical trials in predementia stages of Alzheimer disease. Med Clin North Am. 2013; 97:439-457.
9. Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011; 3:111cm33.
10. Delbeke D, Alessio A, Iagaru A. FDA AD Drug Development Guidance. J Nucl Med. 2013; 54:16N.
11. Bredesen D. mCiRNA-synaptic crystal ball? Aging (Albany NY). 2012; 4:732-733.
12. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007; 13:1359-1362.
13. Reddy MM, Wilson R, Wilson J, Connell S, Gocke A, Hynan L, German D, Kodadek T. Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. Cell. 2011; 144:132-142.
14. Nagele E, Han M, Demarshall C, Belinka B, & Nagele R. Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One. 2011; 6:e23112.
15. Leidinger P, Backes C, Deutscher S, Schmitt K, Muller SC, Frese K, Haas J, Ruprecht K, Paul F, Stahler C, Lang CJ, Meder B, Bartfai T, Meese E, Keller A. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 2013; 14:R78.
16. Geekiyanage H, Jicha GA, Nelson PT, Chan C. Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease. Exp Neurol. 2012; 235:491-496.
17. Provost P. Interpretation and applicability of microRNA data to the context of Alzheimer's and age-related diseases. Aging (Albany NY). 2010; 2:166-169.
18. Kumar P, Dezso Z, Mackenzie C, Oestreicher J, Agoulnik S, Byrne M, Bernier F, Yanagimachi M, Aoshima K, Oda Y. Circulating miRNA Biomarkers for Alzheimer's Disease. PLoS One. 2013; 8:e69807.
19. Bekris LM, Lutz F, Montine TJ, Yu CE, Tsuang D, Peskind ER, Leverenz JB. MicroRNA in Alzheimer's disease: an exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers. 2013; 18:455-466.
20. Sheinerman KS, Tsivinsky VG, Crawford F, Mullan MJ, Abdullah L, Umansky SR. Plasma microRNA biomarkers for detection of mild cognitive impairment. Aging (Albany NY). 2012; 4:590-605.
21. Hennessey PT, Sanford T, Choudhary A, Mydlarz WW, Brown D, Adai AT, Ochs MF, Ahrendt SA, Mambo E, Califano JA. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One. 2012; 7:e32307.
22. Matthaei H, Wylie D, Lloyd MB, Dal Molin M, Kemppainen J, Mayo SC, Wolfgang CL, Schulick RD, Langfield L, Andruss BF, Adai AT, Hruban RH, Szafranska-Schwarzbach AE, Maitra A. miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res. 2012; 18:4713-4724.
23. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabrò E, Croce CM, Pastorino U, Sozzi G. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011; 108:3713-3718.
24. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56:303-308.
25. Mariani E, Monastero R, Mecocci P. Mild cognitive impairment: a systematic review. J Alzheimers Dis. 2007; 12:23-35.
26. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009; 119:252-265.
27. Vo N, Klein ME, Varlamova O, Keller DM, Yamamoto T, Goodman RH, Impey S. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc Natl Acad Sci U S A. 2005; 102:16426-16431.
28. Wayman GA, Davare M, Ando H, Fortin D, Varlamova O, Cheng HY, Marks D, Obrietan K, Soderling TR, Goodman RH, Impey S. An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP. Proc Natl Acad Sci U S A. 2008; 105:90939098.
29. Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, Kiebler M, Greenberg ME. A brain-specific microRNA regulates dendritic spine development. Nature. 2006; 439:283-289.
30. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown D, Chen C, Prinjha RK, Richardson JC, Saunders AM, Roses AD, Richards CA. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis. 2008; 14:27-41.
31. Hébert SS, Wang WX, Zhu Q, Nelson PT. A study of small RNAs from cerebral neocortex of pathology-verified Alzheimer's disease, dementia with lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls. J Alzheimers Dis. 2013; 35:335-348.
32. Lau P, Bossers K, Janky R, Salta E, Frigerio CS, Barbash S, Rothman R, Sierksma AS, Thathiah A, Greenberg D, Papadopoulou AS, Achsel T, Ayoubi T, Soreq H, Verhaagen J, Swaab DF, Aerts S, De Strooper B. Alteration of the microRNA network during the progression of Alzheimer's disease. EMBO Mol Med. 2013; 5:1613-1634.
33. Bruno IG, Karam R, Huang L, Bhardwaj A, Lou CH, Shum EY, Song HW, Corbett MA, Gifford WD, Gecz J, PfaffSL, Wilkinson MF. Identification of a microRNA that activates gene expression by repressing nonsense-mediated RNA decay. Mol Cell. 2011; 42:500-510.
34. Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport. 2007; 18:297-300.
35. Müller M, Kuiperij HB, Claassen JA, Küsters B, Verbeek MM. MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol Aging. 2013 Aug 17 [Epub ahead of print].
36. Dhahbi JM, Spindler SR, Atamna H, Yamakawa A, Guerrero N, Boffelli D, Mote P, Martin DI. Deep sequencing identifies circulating mouse miRNAs that are functionally implicated in manifestations of aging and responsive to calorie restriction. Aging (Albany NY). 2013; 5:130-141